Efficacy of liposomal doxorubicin-based neoadjuvant chemotherapy in patients with breast cancer
LIU Qipeng
GUO Wanying
ZHANG Ting
Abstract：Objective To explore the efficacy of liposomal doxorubicin(DOX)-based neoadjuvant chemotherapy in the treatment of patients with breast cancer.Methods A total of 60 patients with breast cancer admitted to the First Affiliated Hospital of Henan University of Science and Technology from January 2020 to January 2023 were prospectively included and divided into the conventional group and the liposome group by random number table method,with 30 cases in each group.The conventional group received neoadjuvant chemotherapy with DOX and cyclophosphamide(CPA)followed by docetaxel(DTX),while the liposome group received liposomal DOX and CPA followed by DTX.One treatment cycle was defined as 21 days,and both groups were treated for 8 cycles.Both groups were followed up until surgery.The curative effect,surgical treatment condi-tions,incidence of adverse reactions,tumor markers levels,and quality of life before and after treatment were compared between the two groups.Results After 8 cycles of treatment,the total effective rate in the liposome group was 76.67％(23/30),higher than that in the conventional group(50.00％(15/30))(x2=4.593,P＜0.05).The surgical duration and intraoperative blood loss in the liposome group were(73.23±8.68)min and(190.73±17.88)mL,compared to(84.88±7.77)min and(226.31±20.79)mL in the conventional group,with statistically significant differences(t=5.477,7.107,both P＜0.05).After 8 cycles of treatment,the serum levels of carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen,and CA15-3 decreased in the two groups,and the levels in the liposome group((41.42±6.23)U/L,(14.71±2.44)μg/L,(88.37±9.26)U/L,respectively)were lower than those in the conventional group((46.81±5.16)U/L,(19.73±2.12)μg/L,(97.10±9.29)U/L,respectively)(t=3.649,8.506,3.645,all P＜0.05).After 8 cycles of treatment,scores in the functional domains and overall health status improved in both groups,and the scores in the liposome group((78.21±7.37),(74.11±6.17)points)were higher than those in the conventional group((69.06±6.26),(63.00±6.96)points)(t=5.183,6.542,both P＜0.05).Symptom domain scores decreased in both groups,with lower scores in the liposome group((54.05±5.39)points)than in the conventional group((60.67±5.26)points)(t=4.815,P＜0.05).During treatment,the incidence of leukopenia and alopecia in the liposome group(33.33％(10/30)and 26.67％(8/30))was lower than that in the conventional group(60.00％(18/30)and 53.33％(16/30))(x2=4.286,4.444,both P＜0.05).Conclusion Liposomal doxorubi-cin-based neoadjuvant chemotherapy demonstrates favorable efficacy in breast cancer treatment.It improves subsequent surgical outcomes,reduces serum tumor marker levels,enhances patient quality of life,and exhibits a better safety profile.
Keywords：breast cancerliposomal doxorubicinneoadjuvant chemotherapytumor markersquality of life
Publication Date：2026-01-25
Online Publishing Date：2026-03-03(First online date of this platform, not the publication date of the document)
Pages：5( 1-5 )